Evidence map›Paper›PMID 37025023›Full record

Trial reportVascular medicine (London, England)2023

Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.

E Hope Weissler, Amanda Stebbins, Lisa Wruck, Daniel Muñoz, Kamal Gupta, Saket Girotra, Jeff Whittle, Catherine P Benziger, Tamar S Polonsky, Steven M Bradley and 5 more

Abstract readRandomized Controlled TrialPragmatic Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Vascular medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

E Hope WeisslerDuke Clinical Research Institute, Durham, NC, USA.ORCID 0000-0002-8442-6150
Amanda StebbinsDuke Clinical Research Institute, Durham, NC, USA.
Lisa WruckDuke Clinical Research Institute, Durham, NC, USA.
Daniel MuñozVanderbilt University Medical Center, Nashville, TN, USA.
Kamal GuptaUniversity of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0002-2440-9033
Saket GirotraUniversity of Iowa, Iowa City, IA, USA.
Jeff WhittleMedical College of Wisconsin, Milwaukee, WI, USA.
Catherine P BenzigerEssentia Health Heart and Vascular Center, Duluth, MN, USA.
Tamar S PolonskyUniversity of Chicago Medicine, Chicago, IL, USA.
Steven M BradleyAllina Health and Minneapolis Heart Institute, Minneapolis, MN, USA.
Bradley G HammillDuke Clinical Research Institute, Durham, NC, USA.
James G MerrittStudy Patient Partner, Brighton, MI, USA.
Doris N ZemonStudy Patient Partner, Alachua, FL, USA.
Adrian F HernandezDuke Clinical Research Institute, Durham, NC, USA.
W Schuyler JonesDuke Clinical Research Institute, Durham, NC, USA.

Funding

Reducing Ethnic-racial Disparities in Cardiac Arrest Survival Outcomes (RED-CASO)R01HL160734 · NHLBI · SAINT LUKE'S HOSPITAL · PI CHAN, PAUL SHEUNG-YAN, GIROTRA, SAKET · 2022 to 2025
$2.6M
Peripheral Artery Disease: Long-term Survival & Outcomes Study (PEARLS)R56HL158803 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GIROTRA, SAKET · 2021 to 2021
$633k
Addressing variability in peripheral arterial disease outcomes using machine learning techniquesF32HL151181 · NHLBI · DUKE UNIVERSITY · PI WEISSLER, ELIZABETH HOPE · 2020 to 2021
$130k
NHLBI NIH HHS F32 HL151181NHLBI NIH HHS R01 HL160734NHLBI NIH HHS R56 HL158803
6 · The paper itself

Abstract

backgroundWe aimed to understand the effects of aspirin dose on outcomes in patients with peripheral artery disease (PAD) as well as their participation in a pragmatic randomized controlled trial.

methodsIn a subanalysis of the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study, we compared aspirin doses (81 vs 325 mg) among participants with PAD and study participation metrics in patients with and without PAD. The primary outcome composite was all-cause mortality, nonfatal myocardial infarction, and nonfatal stroke.

resultsAmong 14,662 participants enrolled in ADAPTABLE with PAD status available, 3493 (23.8%) had PAD. Participants with PAD were more likely to experience the primary composite (13.76% vs 5.31%,

conclusionsADAPTABLE participants with PAD did not benefit from a higher dose of aspirin and participated in the study differently from those without PAD. These results reinforce the need for additional PAD-specific research and suggest that different trial strategies may be needed for optimal engagement of patients with PAD.

Indexed as

Myocardial InfarctionPeripheral Arterial DiseaseStrokeAspirinDrug Therapy, CombinationHumansPatient-Centered CarePlatelet Aggregation InhibitorsAspirinPlatelet Aggregation Inhibitorsantiplatelet therapyclinical trial methodologyevidence-based medicineperipheral artery disease (PAD)pragmatic trials

Identifiers

PMID37025023
PMCPMC10795754

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.